TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain
- PMID: 7970732
TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain
Abstract
EWS and TLS/FUS genes, which code for RNA binding proteins are involved in a wide variety of human solid tumors. The TLS/FUS gene is involved both in human myxoid liposarcomas which carry a characteristic chromosomal translocation, t(12;16)(q13;p11) and in human myeloid leukemias with recurrent chromosomal translocation, t(16;21)(p11:q22). The TLS/FUS gene is fused to a transcriptional repressor, CHOP (in human myxoid liposarcomas) or transcriptional activator, erg (in human myeloid leukemias). To understand better the functional role of TLS/FUS-erg in human myeloid leukemias, we have cloned the TLS/FUS and TLS/FUS-erg cDNAs and studied the functional properties of their gene products. TLS/FUS protein binds to RNA in vitro and shows preferential binding to poly G. Both the amino- and the carboxy- terminal regions of TLS/FUS containing the conserved RNA binding motifs are needed for poly G specific RNA binding activity. The TLS/FUS fusion domain (TFD) appears to regulate the DNA binding activity of TLS/FUS-erg chimeric protein which shows weaker transcriptional activation properties compared to normal erg proteins. Mutational analysis of the TLS/FUS-erg chimeric protein reveals TFD to function as a transcriptional activation domain thus replacing the amino terminal transcriptional activation domain of the erg protein. Therefore alterations in both DNA binding and transcriptional activation properties of aberrant erg proteins may be responsible for the genesis of t(16;21) chromosomal translocation-bearing human myeloid leukemias.
Similar articles
-
An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation.Cancer Res. 1994 Jun 1;54(11):2865-8. Cancer Res. 1994. PMID: 8187069
-
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.Am J Pathol. 1995 Nov;147(5):1221-7. Am J Pathol. 1995. PMID: 7485386 Free PMC article.
-
Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.Oncogene. 1997 Sep;15(11):1357-62. doi: 10.1038/sj.onc.1201281. Oncogene. 1997. PMID: 9315104
-
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.
-
[AML(M7) associated with t(16;21)(p11;q22) showing relapse after unrelated bone marrow transplantation and disappearance of TLS/FUS-ERG mRNA].Rinsho Ketsueki. 2001 Jun;42(6):502-6. Rinsho Ketsueki. 2001. PMID: 11505530 Review. Japanese.
Cited by
-
Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).J Biol Chem. 2012 Jun 29;287(27):23079-94. doi: 10.1074/jbc.M111.328757. Epub 2012 May 4. J Biol Chem. 2012. PMID: 22563080 Free PMC article.
-
Male sterility and enhanced radiation sensitivity in TLS(-/-) mice.EMBO J. 2000 Feb 1;19(3):453-62. doi: 10.1093/emboj/19.3.453. EMBO J. 2000. PMID: 10654943 Free PMC article.
-
Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers.J Pharm Sci Pharmacol. 2014 Mar;1(1):82-85. doi: 10.1166/jpsp.2014.1008. J Pharm Sci Pharmacol. 2014. PMID: 25679011 Free PMC article.
-
Nuclear localization sequence of FUS and induction of stress granules by ALS mutants.Neurobiol Aging. 2011 Dec;32(12):2323.e27-40. doi: 10.1016/j.neurobiolaging.2010.06.010. Epub 2010 Jul 31. Neurobiol Aging. 2011. PMID: 20674093 Free PMC article.
-
Novel Potential Biomarkers for Opisthorchis viverrini Infection and Associated Cholangiocarcinoma.In Vivo. 2018 Jul-Aug;32(4):871-878. doi: 10.21873/invivo.11321. In Vivo. 2018. PMID: 29936472 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials